miR‑224/miR‑141 ratio as a novel diagnostic biomarker in renal cell carcinoma

Biomarkers to guide the clinical treatment of patients with renal cell carcinoma (RCC) are not yet routinely available. MicroRNAs (miRNAs) have been demonstrated to serve as biomarkers for a number of types of cancer. Based on a previous study by this group, we hypothesize that several highly differentially expressed miRNAs may serve as tissue and plasma biomarkers in patients with RCC. The expression levels of miR‑210, miR‑224 and miR‑141 were analyzed in tissue samples from the same cohort of 78 patients with RCC, in paired pre‑ and post‑operative plasma samples from 66 patients with clear cell RCC (ccRCC) and in 67 healthy controls by reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristic (ROC) was used to evaluate the diagnostic accuracy associated with the expression of miR‑210, miR‑224 and miR‑141. ROC curves revealed that the diagnostic accuracy (area under the curve) of tissue miR‑210, miR‑224, the ratio of miR‑210/miR‑141 (miR210/141), miR‑224/miR‑141 (miR224/141) and miR‑210x miR‑224/miR‑141 (miR210x224/141) in ccRCC was 0.8329, 0.8511, 0.9412, 0.9898 and 0.9771, respectively. Notably, miR224/141 demonstrated the highest accuracy among these miRNAs for discriminating ccRCC tissues from normal tissues, with a sensitivity of 97.06% and a specificity of 98.53%. The expression levels of plasma miR‑210 and miR‑224 were significantly increased in patients compared with healthy control patients, and were reduced postoperatively (P<0.05). The diagnostic accuracy of plasma miR‑210 and miR‑224 were 0.6775 (89.55% sensitivity and 48.48% specificity) and 0.6056 (88.06% sensitivity and 40.91% specificity), respectively. The present study indicated that the tissue miR‑224/miR‑141 ratio is a potentially powerful tool for detecting ccRCC. However, plasma miR‑210 and miR‑224 may not be associated with diagnosis of ccRCC.